Insulin NPH for steroid-induced hyperglycemia: Predictors for success

被引:4
作者
Stone, Andrew C. [1 ]
Dungan, Kathleen [2 ]
Gaborcik, Joshua W. [1 ]
机构
[1] Ohio State Univ, Dept Pharm, Wexner Med Ctr, 410 West 10th Ave, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Internal Med, Div Endocrinol & Metab, Wexner Med Ctr, Columbus, OH 43210 USA
来源
PHARMACOTHERAPY | 2021年 / 41卷 / 10期
关键词
corticosteroid; diabetes; hyperglycemia; insulin NPH; steroid-induced hyperglycemia; GLARGINE; THERAPY;
D O I
10.1002/phar.2616
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective This study aimed to evaluate the efficacy of insulin neutral protamine Hagedorn (NPH) for steroid-induced hyperglycemia and identify factors associated with achievement of euglycemia. Design Retrospective, single center, cohort analysis. Setting Quaternary care academic medical center. Patients Adult patients with steroid-induced hyperglycemia on combination therapy of an intermediate-acting steroid and once daily NPH. Intervention The primary outcome was the percentage of patients who achieved euglycemia on day 3 of combination therapy. Patients were divided into euglycemic and dysglycemic cohorts based on the primary outcome. Univariate analysis on baseline characteristics, NPH dose, and steroid dose based on prednisone equivalent dose (PED) was conducted to identify differences between the cohorts. Safety analysis was conducted to detect differences between the two cohorts. Measurements and Main Results Of 142 patients included in the primary analysis, 50 (35.2%) achieved euglycemia on day 3 of combination therapy. In univariate analysis, patients who achieved euglycemia had significantly higher median NPH dose standardized to steroid dose on day 1 (0.5 units/mg PED [25%-75% interquartile range (IQR) 0.4-0.8] vs 0.4 units/mg PED [0.2-0.8]; p = 0.046), lower median blood glucose prior to combination therapy on day 3 (111 mg/dl [96-160] vs 136 mg/dl [113-198]; p = 0.008), and lower median blood glucose 4 hours after administration of combination therapy on day 3 (147 mg/dl [116-197] vs 190 mg/dl [153-245]; p = 0.003) compared to patients who did not achieve euglycemia, respectively. Hypoglycemia and life-threatening hypoglycemia occurred at similar rates between the two cohorts. Conclusions Neutral protamine Hagedorn is a safe and efficacious option for acute care hospitalized patients experiencing steroid-induced hyperglycemia. More aggressive dosing initiation of NPH based on steroid dose may allow for earlier achievement of euglycemia without a difference in hypoglycemia.
引用
收藏
页码:804 / 810
页数:7
相关论文
共 50 条
  • [1] Optimizing the Treatment of Steroid-Induced Hyperglycemia
    Wallace, Matthew D.
    Metzger, Nicole L.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (01) : 86 - 90
  • [2] Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies
    Healy, Sara J.
    Nagaraja, Haikady N.
    Alwan, Dhuha
    Dungan, Kathleen M.
    ENDOCRINE, 2017, 56 (01) : 90 - 97
  • [3] Modifying Type of Insulin to Manage Steroid-Induced Hyperglycemia: A Case Report
    Pollock, Faith M.
    AACN ADVANCED CRITICAL CARE, 2023, 34 (01) : 39 - 46
  • [4] Implementation of a Weight-Based Protocol for the Management of Steroid-Induced Hyperglycemia
    Myers, Alyson K.
    Khan, Mahmuda
    Choi, Sebastian
    Garnica, Patricia
    Stoffels, Guillaume
    Lin, Amanda
    AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (04) : E392 - E399
  • [5] Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies
    Sara J. Healy
    Haikady N. Nagaraja
    Dhuha Alwan
    Kathleen M. Dungan
    Endocrine, 2017, 56 : 90 - 97
  • [6] USE OF NPH INSULIN FOR GLUCOCORTICOID-INDUCED HYPERGLYCEMIA
    Wang, Cecilia C. Low
    Draznin, Boris
    ENDOCRINE PRACTICE, 2016, 22 (02) : 271 - 273
  • [7] Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review
    Bonaventura, Aldo
    Montecucco, Fabrizio
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 139 : 203 - 220
  • [8] Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases
    Kleinhans, Monika
    Albrecht, Lea Jessica
    Benson, Sven
    Fuhrer, Dagmar
    Dissemond, Joachim
    Tan, Susanne
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024, 18 (04): : 904 - 910
  • [9] Prevalence of Steroid-Induced Hyperglycemia in King Abdulaziz Specialist Hospital, Taif City, Saudi Arabia
    Sarriyah, Jehan F.
    Alghamdi, Adel S.
    Al-Otaibi, Norah M.
    Abdulrahman, Batool B.
    Aljaed, Kholoud M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [10] Optimal initial insulin dosage for managing steroid-induced hyperglycemia in hospitalized COVID-19 patients: A retrospective single-center study
    Ketaroonrut, Nuttavadee
    Kiertiburanakul, Sasisopin
    Sriphrapradang, Chutintorn
    SAGE OPEN MEDICINE, 2024, 12